Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Recruiting · NCT07241546 · Interventional (participants receive a specific treatment) · Lead sponsor: Arrowhead Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
ARO-RAGEPlacebo
What this trial is about
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
- Established allergy confirmed by positive skin prick test at screening
- Willing and able to perform lung function tests and other study-related procedures
- Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later
Exclusion criteria
- Concomitant diagnosis of a clinically important pulmonary disease other than asthma
- Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
- History or current medical condition contraindicating methacholine challenge
- Note: Additional inclusion/exclusion criteria may apply per protocol.
Where it is running
5 locations listed.
- Research Site 2 - Calgary, Canada
- Research Site 3 - Edmonton, Canada
- Research Site 5 - Hamilton, Canada
- Research Site 4 - Saskatoon, Canada
- Research Site 1 - Vancouver, British Columbia, Canada